Specificities, properties, and clinical significance of antiprothrombin antibodies

Amengual, Olga; Atsumi, Tatsuya; Koike, Takao

doi:10.1002/art.10831

Cited by 62 publications

(35 citation statements)

References 65 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Anti-PT ELISA and anti-PT/PS ELISA probably do not detect identical antibody populations as there is no correlation between the titers of anti-PT and anti-PS/PT in patients with APS, and a monoclonal anti-PS/PT was unable to bind to PT coated directly onto oxidized microtiter plates. 104,105 It has been suggested that the anti-PS/PT ELISA is more sensitive than the anti-PT ELISA 106 and that anti-PS/PT are more closely associated with the clinical manifestations of APS. 104 However, these assays have not been evaluated for precision and interlaboratory variation, and no attempt has been made toward standardization.…”

Section: Antibodies Against Prothrombinmentioning

confidence: 99%

Antiphospholipid Antibodies: Laboratory and Pathogenetic Aspects

Vlachoyiannopoulos

Samarkos

Sikara

et al. 2007

Critical Reviews in Clinical Laboratory Sciences

View full text Add to dashboard Cite

Antiphospholipid antibodies (aPL) constitute a heterogeneous group of autoantibodies that share the ability to bind phospholipids (PL) alone, protein-PL complexes, or PL-binding proteins. They have been detected in isolation, in association with autoimmune diseases such as systemic lupus erythematosus (SLE), and during the course of different infections. aPL have been associated with an array of clinical manifestations in virtually every organ, although deep vein and arterial thrombosis as well as pregnancy morbidity are predominant. The co-occurrence of these clinical findings with aPL constitutes the so-called antiphospholipid syndrome (APS). aPL can be detected by immunological methods [e.g., anticardiolipin antibodies (aCL)] or by functional methods that exploit the effect of aPL on blood coagulation [lupus anticoagulant (LA)]. Since aPL are heterogeneous, numerous immunological and coagulation assays have been developed. These assays have not been fully standardized, and, therefore, problems such as high interlaboratory variation are relatively frequent. Recently, recommendations have been published regarding LA and aCL testing. Not all aPL are pathogenic. However, when they are not associated with infections, they have a role in the pathogenesis of APS. Clinical and experimental data have shown that aPL exert their pathogenic activity by interfering with the function of coagulation factors, such as thrombin and factors X, XI and XII, and with the function of anticoagulant proteins of the protein C system. In addition, aPL interaction with platelets and endothelial cells induces a pro-adhesive activated phenotype.

show abstract

Section: Antibodies Against Prothrombinmentioning

confidence: 99%

Antiphospholipid Antibodies: Laboratory and Pathogenetic Aspects

Vlachoyiannopoulos

Samarkos

Sikara

et al. 2007

Critical Reviews in Clinical Laboratory Sciences

View full text Add to dashboard Cite

show abstract

“…The antiprothrombin antibody family comprises two types of antibodies: those detected by ELISA using prothrombin alone as the target antigen (aPT-A) and those directed against phosphatidylserine-prothrombin complexes, the so-called phosphatidylserine-dependent antiprothrombin antibodies (aPS/PT) [2]. Numerous studies have investigated the implications of aPT-A in the clinical manifestation of APS with controversial results [3][4][5][6].…”

Section: Introductionmentioning

confidence: 99%

Comparative analysis of different enzyme immunoassays for assessment of phosphatidylserine-dependent antiprothrombin antibodies

et al. 2014

Self Cite

View full text Add to dashboard Cite

Phosphatidylserine-dependent antiprothrombin antibodies (aPS/PT) were strongly correlated with the presence of lupus anticoagulant showing a high specificity for the diagnosis of antiphospholipid syndrome. However, the main criticism for the clinical applicability of aPS/PT testing is the lack of reproducibility of the results among laboratories. In this study, we measured IgG and IgM aPS/PT using our original in-house enzyme-linked immunosorbent assays (ELISA) and commercial ELISA kits to assess the assay performance and to evaluate the accuracy of aPS/PT results.The study included 111 plasma samples collected from patients and stored at our laboratory for aPS/PT assessment. Sixty-one samples were tested for IgG aPS/PT using two assays: 1) aPS/PT ELISA in-house ELISA and 2) QUANTA Lite In conclusion, IgG and IgM detection by ELISA is accurate. The performance of aPS/PT is reliable and concordant results can be obtained using different ELISA methods.

show abstract

“…APS is a possible cause of pregnancy loss through the promotion of microvascular placental thrombosis, which is frequently associated with infarction, perivillous fibrin deposits, and chronic inflammatory lesions (13 ). Antiprothrombin (aPT) antibodies, which are present in ϳ50% of antiphospholipid-positive patients (14 ) and are frequently found in women with APS, show wide variation in immunological and functional properties, depending mainly on their affinity for human prothrombin (or factor II), a vitamin K-dependent glycoprotein that performs several anticoagulant activities (15 ). The clinical relevance in RSA of aPT antibodies has not been established despite increasing knowledge about their mechanism(s) of action and their presence in a number of conditions associated with venous thromboembolism and the hypercoagulable state of APS (15 ).…”

mentioning

confidence: 99%